Participants were randomized to DTaP5-IPV-Hib-HepB plus PCV7 , DTaP5-IPV-Hib-HepB with PCV7 administered 1 month later or a pentavalent DTaP5-IPV/Hib plus HepB plus PCV7 at 15 months of age in a randomized , open-label , phase IIb clinical trial .